Aurinia Pharmaceuticals

+$5.91 (+26.75%) Today
+$2.40 (+8.57%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AUPH and other ETFs, options, and stocks.

About AUPH

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

CEO
Peter S. Greenleaf
Employees
294
Headquarters
Victoria, British Columbia
Founded
1993

AUPH Key Statistics

Market Cap
3.60B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
3.02M
High Today
$24.44
Low Today
$21.68
Open Price
$21.95
Volume
9.56M
52 Week High
$28.00
52 Week Low
$9.72

AUPH News

BloombergOct 22

Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals

(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to peop
Simply Wall StOct 18

Market Sentiment Around Loss-Making Aurinia Pharmaceuticals Inc.

We feel now is a pretty good time to analyse Aurinia Pharmaceuticals Inc.'s ( ) business as it appears the company may be on the cusp of a considerable accompli

AUPH Earnings

-$0.40
-$0.27
-$0.13
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
— per share
Actual
Expected Nov 9, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure